Health & Research Goals
LL-37
Antimicrobial & Immune Modulation — The Only Human Cathelicidin
Primary Description
LL-37, also called cathelicidin, is the only cathelicidin antimicrobial peptide found in humans. It is encoded by the CAMP gene on chromosome 3p21.3 and is cleaved from the precursor protein hCAP18 (human cationic antimicrobial peptide 18 kDa) by protease-3 to produce the active 37-amino acid peptide starting with two leucine residues (hence 'LL-37'). LL-37 is an important part of the human innate immune system, capable of resisting various pathogens including bacteria, viruses, and fungi. Beyond its direct antimicrobial activity, it has multifunctional immunomodulatory effects that bridge innate and adaptive immunity, regulate inflammation, promote wound healing, and influence cancer biology. It exhibits dual context-dependent functionality — pro-inflammatory to fight infections and anti-inflammatory to prevent excessive damage — described as 'two sides of the same coin.'
Key Benefits
- Antimicrobial activity
- Wound healing
- Immune modulation
Demonstrated Effects
- Broad-spectrum antibacterial activity (Gram-positive and Gram-negative bacteria)
- Antiviral activity
- Antifungal effects
- Anti-biofilm properties
- Accelerated wound closure and angiogenesis promotion (VEGF-A stimulation)
- Keratinocyte migration enhancement
- Diabetic wound healing enhancement
- Immune cell chemotaxis and recruitment
- Cytokine/chemokine regulation bridging innate and adaptive immunity
- LPS neutralization (endotoxin binding) — prevents cytokine storm
- Sepsis treatment potential
Proposed Mechanisms of Action
Research Evidence & Clinical Data
Investigated Applications
Wound Healing
Anecdotal: HighAccelerated wound closure, angiogenesis promotion via VEGF-A stimulation, keratinocyte migration, and diabetic wound healing enhancement. Applied as 0.1–1% cream or hydrogel to wound bed.
Preclinical basis: Miranda et al. (2023) Wound Repair Regen: demonstrated enhanced healing and reduced inflammatory markers (IL-1α, TNF-α) in diabetic foot ulcers. Ramos et al. (2011) J Invest Dermatol showed LL-37 stimulates VEGF-A and accelerates wound closure. Heilborn et al. (2003) J Invest Dermatol confirmed keratinocyte migration effects.
Antimicrobial Defense
Anecdotal: MediumBroad-spectrum antibacterial (Gram+ and Gram−), antiviral, antifungal, and anti-biofilm activity. Membrane disruption mechanism distinct from conventional antibiotics.
Preclinical basis: Duplantier et al. (2013) Front Immunol detailed broad-spectrum antibacterial and anti-biofilm effects. Nizet (2006) J Leukoc Biol highlighted membrane disruption and immunomodulatory properties.
Immune Modulation
Anecdotal: MediumDual pro- and anti-inflammatory roles. Pro-inflammatory: immune cell recruitment, cytokine production, antitumor activity. Anti-inflammatory: LPS neutralization, cytokine storm prevention, tissue repair. Defects in LL-37 expression can break immune equilibrium.
Preclinical basis: Yang et al. (2020) Biomed Res Int demonstrated LL-37's dual pro- and anti-inflammatory roles. Scott et al. (2002) J Immunol demonstrated LPS binding and TLR4 inhibition.
Sepsis
Anecdotal: LowLPS neutralization potential for sepsis treatment. LL-37 binds endotoxin and inhibits TLR4 signaling, preventing excessive inflammatory cascade.
Preclinical basis: Scott et al. (2002) J Immunol demonstrated LL-37 neutralizes LPS and prevents endotoxin shock via TLR4 inhibition.
Inflammatory Skin Conditions
Anecdotal: MediumLL-37 has complex roles in skin disease. Deficiency may contribute to susceptibility to infections; overexpression is implicated in rosacea, psoriasis, and atopic dermatitis. Topical application for wound healing in skin conditions.
Preclinical basis: Moreno-Angarita et al. (2019) Front Immunol reviews LL-37 dysregulation in psoriasis, rosacea, and atopic dermatitis.
Scientific References
- 1.The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm AgentAntibiotics (Basel)2021
- 2.LL-37, the master antimicrobial peptide, its multifaceted role from combating infections to cancer immunityInt J Antimicrob Agents2025
- 3.
Safety Profile
Common Side Effects
- Topical — mild irritation, localized redness, occasional itching (generally well-tolerated)
- Systemic — injection site reactions (redness, swelling, discomfort)
- Flu-like symptoms — possible with immune activation
- Inflammatory flares — in susceptible individuals
- Cancer — context-dependent effects (pro- or anti-tumor; requires monitoring)
- Autoimmunity — may exacerbate certain autoimmune conditions
- Worsening rosacea or psoriasis — can worsen inflammatory skin diseases
- Atherosclerosis — LL-37 found in plaques, cardiovascular role unclear
- Injection site reactions
Contraindications
- Known hypersensitivity to LL-37 or related peptides
- Active malignancy — context-dependent cancer effects
- Pregnancy and breastfeeding — insufficient safety data
- Severe autoimmune disease — may exacerbate in some contexts
- Inflammatory skin conditions (rosacea, psoriasis) — may worsen
- Atherosclerosis — effects unclear
- Uncontrolled inflammatory disorders
- Children under 18 — insufficient pediatric data
- Autoimmune conditions
Research Protocols
Dosing Protocols
Monitoring & Risk Management
No Specific Monitoring Protocol
No structured monitoring data is available for this compound. Always consult a healthcare professional before use.